Glycominds Joins Biomolecular Photonic Consortium
Biodiagnostics company Glycominds Ltd. of Lod, Israel, maker of a blood test for detecting inflammatory bowel disease and the severity of Crohn's disease, announced this week it has joined the Biomolecular Photonic (BMP) Consortium. "Glycominds' glycan biomarker technology stands out as innovative and unique, providing the consortium with proven biomarkers for Crohn's disease and a great opportunity for diagnosing colorectal cancer," said Dr. Elisha Rabinovitz, the head of the BMP consortium and chief scientist for Given Imaging Ltd. BMP is a new, three-year consortium funded by the government of Israel to improve in vivo imaging diagnostics for Crohn's disease and colorectal cancer. The consortium has received $4 million in funding for its first year.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024